文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

2016-2021年世界卫生组织非洲区域乙型肝炎控制及阻断母婴传播进展

Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-07-21

慢性乙型肝炎病毒(HBV)感染是肝硬化和肝癌的主要病因之一。2016年世界卫生大会提出消除HBV母婴传播(EMTCT)目标:及时乙型肝炎疫苗(HepB)出生剂量(HepB-BD)和3剂婴儿HepB(HepB3)覆盖率均≥90%,且≤5岁儿童乙型肝炎表面抗原(HBsAg)血清流行率≤0.1%。至2021年,该区域47国均提供HepB3,14国(30%)提供HepB-BD;16国(34%)达到HepB3覆盖率≥90%,仅2国(4%)达到及时HepB-BD覆盖率≥90%。

要点

  • 至2021年,非洲区域47国均提供HepB3,14国(30%)提供HepB-BD。
  • 16国(34%)达到HepB3覆盖率≥90%,仅2国(4%)达到及时HepB-BD覆盖率≥90%。

核心结论

  • 非洲区域在乙型肝炎控制及阻断母婴传播方面取得一定进展,但及时HepB-BD覆盖率及儿童HBsAg血清流行率达标情况距EMTCT目标仍有差距。
  • COVID-19大流行后免疫恢复计划的制定为加速乙型肝炎控制和EMTCT进展提供了机会,包括引入HepB-BD并提高及时HepB-BD和HepB3接种覆盖率。
  • 需要开展儿童代表性HBsAg血清学调查并建立区域EMTCT验证机构以监测进展。

研究设计与样本

  • 基于WHO非洲区域2016-2021年数据,描述乙型肝炎控制及阻断母婴传播进展的监测报告。

主要发现

  • 至2021年,非洲区域全部47国均向婴儿提供HepB3(自6周龄开始),14国(30%)提供HepB-BD。
  • 截至2021年12月,16国(34%)达到HepB3覆盖率≥90%,仅2国(4%)达到及时HepB-BD覆盖率≥90%。
  • 8国(17%)在HepB引入后出生儿童中开展全国血清学调查:6国达到≤2%血清流行率,但无一国达到≤0.1%血清流行率。

关键数值与推荐

  • 2016年世界卫生大会提出EMTCT目标:及时HepB-BD和HepB3覆盖率均≥90%,且≤5岁儿童HBsAg血清流行率≤0.1%。
  • 2016年WHO非洲区域委员会提出到2020年发病率降低30%(≤5岁儿童HBsAg血清流行率≤2%)且HepB3覆盖率≥90%的目标。

临床怎么用

  • 制定COVID-19大流行后免疫恢复计划,包括引入HepB-BD并提高及时HepB-BD和HepB3接种覆盖率,以加速实现乙型肝炎控制和EMTCT。
  • 开展儿童代表性HBsAg血清学调查并建立区域EMTCT验证机构以监测进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hepatitis B virus (HBV) infection is one of the leading causes of cirrhosis and liver cancer. In 2019, approximately 1.5 million persons newly acquired chronic HBV infection; among these, 990,000 (66%) were in the World Health Organization (WHO) African Region (AFR). Most chronic HBV infections are acquired through mother-to-child transmission (MTCT) or during early childhood, and approximately two thirds of these infections occur in AFR. In 2016, the World Health Assembly endorsed the goal of elimination of mother-to-child transmission (EMTCT) of HBV, documented by ≥90% coverage with both a timely hepatitis B vaccine (HepB) birth dose (HepB-BD) and 3 infant doses of HepB (HepB3), and ≤0.1% hepatitis B surface antigen (HBsAg) seroprevalence among children aged ≤5 years. In 2016, the WHO African Regional Committee endorsed targets for a 30% reduction in incidence (≤2% HBsAg seroprevalence in children aged ≤5 years) and ≥90% HepB3 coverage by 2020. By 2021, all 47 countries in the region provided HepB3 to infants beginning at age 6 weeks, and 14 countries (30%) provided HepB-BD. By December 2021, 16 (34%) countries achieved ≥90% HepB3 coverage, and only two (4%) achieved ≥90% timely HepB-BD coverage. Eight countries (17%) conducted nationwide serosurveys among children born after the introduction of HepB to assess HBsAg seroprevalence: six countries had achieved ≤2% seroprevalence, but none had achieved ≤0.1% seroprevalence among children. The development of immunization recovery plans following the COVID-19 pandemic provides an opportunity to accelerate progress toward hepatitis B control and EMTCT, including introducing HepB-BD and increasing coverage with timely HepB-BD and HepB3 vaccination. Representative HBsAg serosurveys among children and a regional verification body for EMTCT of HBV will be needed to monitor progress.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Kabore HJ, Li X, Alleman MM, et al. Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37471264. doi:10.15585/mmwr.mm7229a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。